ADA and cardiovascular disorder: All of this underlines that combined therapy of ADA inhibitors with nucleoside transport inhibitors may have synergistic benefits resulting from the primary drug effect (as ticagrelor affects platelets) and the effects on the retention of adenosine and nucleoside-derived ADA inhibitors in the extracellular compartment, which could be especially important for the treatment of cardiovascular diseases [104].